

# Raban V Jeger

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7798798/publications.pdf>

Version: 2024-02-01

151  
papers

18,466  
citations

101496

36  
h-index

12933

131  
g-index

162  
all docs

162  
docs citations

162  
times ranked

16787  
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and Efficacy of Drug-Coated Balloons Versus Drug-Eluting Stents in Acute Coronary Syndromes: A Prespecified Analysis of BASKET-SMALL 2. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, CIRCINTERVENTIONS121011325.	1.4	15
2	Soluble urokinase plasminogen activator receptor and functionally relevant coronary artery disease: a prospective cohort study. <i>Biomarkers</i> , 2022, 27, 278-285.	0.9	2
3	Drug-coated balloons for small coronary artery disease in patients with chronic kidney disease: a pre-specified analysis of the BASKET-SMALL 2 trial. <i>Clinical Research in Cardiology</i> , 2022, 111, 806-815.	1.5	8
4	Drug-Coated Balloon for Small Coronary Artery Disease in Patients With and Without High-Bleeding Risk in the BASKET-SMALL 2 Trial. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, 101161CIRCINTERVENTIONS121011569.	1.4	17
5	First-in-man concomitant mitral valve replacement and coronary artery bypass grafting using a single minimally invasive access. <i>European Journal of Cardio-thoracic Surgery</i> , 2022, 62, .	0.6	3
6	Causes of death after treatment of small coronary artery disease with paclitaxel-coated balloons. <i>Clinical Research in Cardiology</i> , 2021, 110, 307-311.	1.5	6
7	Four-year mortality in women and men after transfemoral transcatheter aortic valve implantation using the SAPIEN 3. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 876-884.	0.7	10
8	Transcatheter Aortic Valve Replacement With the LOTUS Edge System. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 172-181.	1.1	6
9	Infective endocarditis: prevention and antibiotic prophylaxis. <i>Swiss Medical Weekly</i> , 2021, 151, w20473.	0.8	2
10	Effect of COVID-19 on acute treatment of ST-segment elevation and Non-ST-segment elevation acute coronary syndrome in northwestern Switzerland. <i>IJC Heart and Vasculature</i> , 2021, 32, 100686.	0.6	7
11	A review of recommendations for infective endocarditis prevention in patients undergoing transcatheter aortic valve implantation. <i>EuroIntervention</i> , 2021, 16, 1135-1140.	1.4	21
12	Incidence and outcomes of perioperative myocardial infarction/injury diagnosed by high-sensitivity cardiac troponin I. <i>Clinical Research in Cardiology</i> , 2021, 110, 1450-1463.	1.5	18
13	Coronary and structural heart interventions in Switzerland 2019. <i>Swiss Medical Weekly</i> , 2021, 151, w20495.	0.8	3
14	Age-Related Outcomes After Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 952-960.	1.1	28
15	Impact of anemia on short-term outcomes after TAVR : A subgroup analysis from the BRAVO randomized trial. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E870-E880.	0.7	2
16	Non-invasive predictors for infranodal conduction delay in patients with left bundle branch block after TAVR. <i>Clinical Research in Cardiology</i> , 2021, 110, 1967-1976.	1.5	0
17	Impact of Diabetes on Outcome With Drug-Coated Balloons Versus Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1789-1798.	1.1	22
18	Drug-coated Balloons for Small Coronary Disease – A Literature Review. <i>Current Cardiology Reports</i> , 2021, 23, 173.	1.3	4

#	ARTICLE	IF	CITATIONS
19	Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement. <i>New England Journal of Medicine</i> , 2020, 382, 130-139.	13.9	194
20	Drug-coated balloons in cardiovascular disease: benefits, challenges, and clinical applications. <i>Expert Opinion on Drug Delivery</i> , 2020, 17, 201-211.	2.4	20
21	Clinical outcomes after TAVR with heparin or bivalirudin as periprocedural anticoagulation in patients with and without peripheral arterial disease: Results from the BRAVO randomized trial. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, E377-E386.	0.7	5
22	Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial. <i>Lancet</i> , The, 2020, 396, 1504-1510.	6.3	96
23	Long-term Results After Drug-eluting Versus Bare-metal Stent Implantation in Saphenous Vein Grafts: Randomized Controlled Trial. <i>Journal of the American Heart Association</i> , 2020, 9, e017434.	1.6	7
24	Using High-Sensitivity Cardiac Troponin for the Exclusion of Inducible Myocardial Ischemia in Symptomatic Patients. <i>Annals of Internal Medicine</i> , 2020, 172, 175.	2.0	14
25	Heavy Drinking Habits Are Associated with Worse In-Hospital Outcomes in Patients with Acute Coronary Syndrome: An Insight from the AMIS Plus Registry. <i>Cardiology</i> , 2020, 145, 757-765.	0.6	2
26	Two cases of successful treatment of acute right heart failure with Impella RP®. <i>ESC Heart Failure</i> , 2020, 7, 1982-1986.	1.4	2
27	Drug-Coated Balloons for Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1391-1402.	1.1	218
28	Infective Endocarditis After Transcatheter Aortic Valve Replacement. <i>Journal of the American College of Cardiology</i> , 2020, 75, 3020-3030.	1.2	60
29	A Randomized Trial of Recombinant Human C1-Esterase-Inhibitor in the Prevention of Contrast-Induced Kidney Injury. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 833-842.	1.1	10
30	Sex-Specific Management in Patients With Acute Myocardial Infarction and Cardiogenic Shock. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008537.	1.4	35
31	Electrophysiology Testing to Stratify Patients With Left Bundle Branch Block After Transcatheter Aortic Valve Implantation. <i>Journal of the American Heart Association</i> , 2020, 9, e014446.	1.6	23
32	Survival After Coronary Revascularization With Paclitaxel-Coated Balloons. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1017-1028.	1.2	70
33	Drug-coated balloon versus drug-eluting stent in small coronary artery lesions: angiographic analysis from the BASKET-SMALL 2 trial. <i>Clinical Research in Cardiology</i> , 2020, 109, 1114-1124.	1.5	18
34	Impact of mitral regurgitation aetiology on MitraClip outcomes: the MitraSwiss registry. <i>EuroIntervention</i> , 2020, 16, e112-e120.	1.4	14
35	Coronary and structural heart interventions in Switzerland 2018. <i>Swiss Medical Weekly</i> , 2020, 150, w20200.	0.8	1
36	Clinical Outcomes of the Portico Transcatheter Aortic Valve Delivered via Alternative Access: 30-Day and 1-Year Results of the Portico ALT Study. <i>Journal of Invasive Cardiology</i> , 2020, 32, 405-411.	0.4	0

#	ARTICLE	IF	CITATIONS
37	2018 ESC/EACTS Guidelines on myocardial revascularization. <i>European Heart Journal</i> , 2019, 40, 87-165.	1.0	4,537
38	2018 ESC/EACTS Guidelines on myocardial revascularization. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 55, 4-90.	0.6	402
39	Impact of Diabetes Mellitus in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007734.	1.4	6
40	Early Diagnosis of Myocardial Infarction in Patients With a History of Coronary Artery Bypass Grafting. <i>Journal of the American College of Cardiology</i> , 2019, 74, 587-589.	1.2	7
41	Do ultrathin strut bare-metal stents with passive coating improve efficacy in large coronary arteries? Insights from the randomized, multicenter BASKET-PROVE trials. <i>BMC Cardiovascular Disorders</i> , 2019, 19, 226.	0.7	1
42	TCT-803 Clinical Outcomes After TAVR in Patients With and Without Peripheral Arterial Disease: Results From the BRAVO-3 Randomized Trial. <i>Journal of the American College of Cardiology</i> , 2019, 74, B787.	1.2	0
43	Impact of diabetes mellitus on short term vascular complications after TAVR: Results from the BRAVO-3 randomized trial. <i>International Journal of Cardiology</i> , 2019, 297, 22-29.	0.8	10
44	Local Versus General Anesthesia for Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1874-1876.	1.1	3
45	The hospital results and 1-year outcomes of transcatheter aortic valve-in-valve procedures and transcatheter aortic valve implantations in the native valves: the results from the Swiss-TAVI Registry. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 56, 55-63.	0.6	32
46	Competing risks of major bleeding and thrombotic events with prasugrel-based dual antiplatelet therapy after stent implantation - An observational analysis from BASKET-PROVE II. <i>PLoS ONE</i> , 2019, 14, e0210821.	1.1	5
47	Impact of percutaneous closure device type on vascular and bleeding complications after TAVR: A post hoc analysis from the BRAVO-3 randomized trial. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 1374-1381.	0.7	35
48	Drug-coated balloons: room for development of BASKET-SMALL 2 – Authors' reply. <i>Lancet, The</i> , 2019, 393, 1934-1935.	6.3	0
49	Prevalence and determinants of exercise-induced left ventricular dysfunction in patients with coronary artery disease. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13112.	1.7	0
50	Perioperative major adverse cardiac events in urgent femoral artery repair after coronary stenting are less common than previously reported. <i>Journal of Vascular Surgery</i> , 2019, 70, 216-223.	0.6	0
51	Twenty-Year Trends in the Incidence and Outcome of Cardiogenic Shock in AMIS Plus Registry. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007293.	1.4	72
52	Drug-eluting stents in large coronary vessels improve both safety and efficacy compared with bare-metal stents in women: a pooled analysis of the BASKET-PROVE I and II trials. <i>Open Heart</i> , 2019, 6, e000986.	0.9	4
53	Clinical utility of circulating interleukin-6 concentrations in the detection of functionally relevant coronary artery disease. <i>International Journal of Cardiology</i> , 2019, 275, 20-25.	0.8	10
54	Temporal trends in adoption and outcomes of transcatheter aortic valve implantation: a SwissTAVI Registry analysis. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2019, 5, 242-251.	1.8	59

#	ARTICLE	IF	CITATIONS
55	New-onset or Pre-existing Atrial Fibrillation in Acute Coronary Syndromes: Two Distinct Phenomena With a Similar Prognosis. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2019, 72, 383-391.	0.4	10
56	Drug-coated Balloons for Small Coronary Vessel Interventions: A Literature Review. <i>Interventional Cardiology Review</i> , 2019, 14, 131-136.	0.7	14
57	Effects of Body Mass Index on Clinical Outcomes in Female Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 68-76.	1.1	28
58	Effect of Increasing Stent Length on 3-Year Clinical Outcomes in Women Undergoing Percutaneous Coronary Intervention With New-Generation Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 53-65.	1.1	22
59	Drug-coated balloons for de novo lesions in small coronary arteries: rationale and design of BASKET-SMALL 2. <i>Clinical Cardiology</i> , 2018, 41, 569-575.	0.7	13
60	Second generation drug-eluting stents versus bare-metal stents for percutaneous coronary intervention of the proximal left anterior descending artery: An analysis of the BASKET-PROVE I and II trials. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 867-873.	0.7	4
61	2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. <i>European Heart Journal</i> , 2018, 39, 119-177.	1.0	7,100
62	Supra-annular sizing for transcatheter valve implantation in bicuspid aortic stenosis. <i>Postepy W Kardiologii Interwencyjnej</i> , 2018, 14, 187-190.	0.1	5
63	Stents in saphenous vein grafts. <i>Lancet, The</i> , 2018, 391, 1967-1968.	6.3	5
64	Direct Comparison of Cardiac Troponin T and I Using a Uniform and a Sex-Specific Approach in the Detection of Functionally Relevant Coronary Artery Disease. <i>Clinical Chemistry</i> , 2018, 64, 1596-1606.	1.5	19
65	Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial. <i>Lancet, The</i> , 2018, 392, 849-856.	6.3	263
66	Long-term outcomes in patients with rheumatologic disorders undergoing percutaneous coronary intervention: a Basel Stent Kosten-Effektivitäts Trial-PROspective Validation Examination (BASKET-PROVE) sub-study. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 778-786.	0.4	10
67	Impact of pre-existing or new-onset atrial fibrillation on 30-day clinical outcomes following transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 90, 1027-1037.	0.7	8
68	Heart failure in patients admitted for acute coronary syndromes: A report from a large national registry. <i>Clinical Cardiology</i> , 2017, 40, 907-913.	0.7	13
69	Predictors and prognostic impact of silent coronary artery disease in asymptomatic high-risk patients with diabetes mellitus. <i>International Journal of Cardiology</i> , 2017, 244, 37-42.	0.8	32
70	Predicting Mortality After Transcatheter Aortic Valve Replacement. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	1.4	32
71	Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction. <i>JAMA Cardiology</i> , 2017, 2, 855.	3.0	25
72	Frequency of Cardiac Death and Stent Thrombosis in Patients With Chronic Obstructive Pulmonary Disease Undergoing Percutaneous Coronary Intervention (from the BASKET-PROVE I and II Trials). <i>American Journal of Cardiology</i> , 2017, 119, 14-19.	0.7	12

#	ARTICLE	IF	CITATIONS
73	The Neurocardiogenic Spectrum in Subarachnoid Hemorrhage: A Case Report and Review of the Literature. <i>Clinical Practice and Cases in Emergency Medicine</i> , 2017, 1, 16-21.	0.1	4
74	Comparison of procedural and clinical outcomes with Evolut R versus Medtronic CoreValve: a Swiss TAVI registry analysis. <i>EuroIntervention</i> , 2017, 12, e2170-e2176.	1.4	51
75	First-generation paclitaxel- vs. second-generation zotarolimus-eluting stents in small coronary arteries: the BASKET-SMALL Pilot Study. <i>Postępy W Kardiologii Interwencyjnej</i> , 2016, 4, 314-320.	0.1	6
76	TCT-312 Increased Cardiac Death and Stent Thrombosis in Chronic Obstructive Pulmonary Disease Patients Undergoing Percutaneous Coronary Intervention. An analysis of the BASKET-PROVE I and II trials. <i>Journal of the American College of Cardiology</i> , 2016, 68, B129.	1.2	4
77	TCT-475 Effect of Stent Diameter in Women Undergoing Percutaneous Coronary Intervention with Early- and New-Generation Drug-Eluting Stents: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. <i>Journal of the American College of Cardiology</i> , 2016, 68, B191.	1.2	0
78	Repositionable Versus Balloon-Expandable Devices for Transcatheter Aortic Valve Implantation in Patients With Aortic Stenosis. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	25
79	Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Artery Revascularization. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 674-684.	1.1	51
80	Correlates and Impact of Coronary Artery Calcifications in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1890-1901.	1.1	32
81	Incidence and Predictors of Cardiomyocyte Injury in Elective Coronary Angiography. <i>American Journal of Medicine</i> , 2016, 129, 537.e1-537.e8.	0.6	4
82	Effect of Chronic Kidney Disease in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 28-38.	1.1	31
83	Safety and Efficacy of New-Generation Drug-Eluting Stents in Women at High Risk for Atherothrombosis. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, e002995.	1.4	12
84	Letter by Jeger and Pfisterer Regarding Article, "Prasugrel Plus Aspirin Beyond 12 Months Is Associated With Improved Outcomes After TAXUS Libert <sup>®</sup> Paclitaxel-Eluting Coronary Stent Placement". <i>Circulation</i> , 2015, 132, e165.	1.6	0
85	Duration of Dual Antiplatelet Therapy after Drug-Eluting Stents. <i>New England Journal of Medicine</i> , 2015, 372, 1371-1374.	13.9	18
86	Long-Term Efficacy and Safety of Biodegradable-Polymer Biolimus-Eluting Stents. <i>Circulation</i> , 2015, 131, 74-81.	1.6	87
87	Bivalirudin Versus Heparin Anticoagulation in Transcatheter Aortic Valve Replacement. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2860-2868.	1.2	116
88	Procedural Results and Clinical Outcomes of Transcatheter Aortic Valve Implantation in Switzerland. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, .	1.4	64
89	Impact of Clinical Presentation (Stable Angina Pectoris vs Unstable Angina Pectoris or Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 Outcomes in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. <i>American Journal of Cardiology</i> , 2015, 116, 845-852.	0.7	32
90	Improved outcomes of elderly patients treated with drug-eluting versus bare metal stents in large coronary arteries: Results from the BASel Stent Kosten-Effektivitäts Trial PROspective Validation Examination randomized trial. <i>American Heart Journal</i> , 2015, 170, 787-795.e1.	1.2	11

#	ARTICLE	IF	CITATIONS
91	Abstract 16776: Drug-eluting Stents in Large Coronary Vessels Improve Both Safety and Efficacy in Women Compared to Bare-metal Stents. <i>Circulation</i> , 2015, 132, .	1.6	0
92	Abstract 16775: Efficacy and Safety of a Thinner-strut Silicon Carbide-coated Cobalt Chromium Bare-metal Stent Compared to a Thin-strut Uncoated Cobalt Chromium Bare-metal Stent in Large Vessel Stenting: Insights From Two Prospective Randomised All-comers Trials. <i>Circulation</i> , 2015, 132, .	1.6	0
93	Prolonged dual antiplatelet therapy in renal failure: a challenging trade-off. <i>Journal of Thoracic Disease</i> , 2015, 7, E625-8.	0.6	1
94	Single-Center Experience and Short-term Outcome with the JenaValve: A Second-Generation Transapical Transcatheter Aortic Valve Implantation Device. <i>Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery</i> , 2014, 9, 368-374.	0.4	5
95	Pacemaker Implantation and Need for Ventricular Pacing during Follow-up after Transcatheter Aortic Valve Implantation. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2014, 37, 1592-1601.	0.5	37
96	Prognostic Value of "Routine" Cardiac Stress Imaging 5 Years After Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 615-621.	1.1	25
97	Tradeoff between bleeding and stent thrombosis in different dual antiplatelet therapy regimes: Importance of case fatality rates and effective treatment durations. <i>American Heart Journal</i> , 2014, 168, 698-705.e2.	1.2	9
98	Percutaneous Mitral Valve Edge-to-Edge Repair. <i>Journal of the American College of Cardiology</i> , 2014, 64, 875-884.	1.2	398
99	Progression to Overt or Silent CAD in Asymptomatic Patients With Diabetes Mellitus at High Coronary Risk. <i>JACC: Cardiovascular Imaging</i> , 2014, 7, 1001-1010.	2.3	70
100	Acute multivessel revascularization improves 1-year outcome in ST-elevation myocardial infarction. <i>International Journal of Cardiology</i> , 2014, 172, 76-81.	0.8	34
101	Short-term clinical outcomes among patients undergoing transcatheter aortic valve implantation in Switzerland: the Swiss TAVI registry. <i>EuroIntervention</i> , 2014, 10, 982-989.	1.4	57
102	First-in-man Portico® transcatheter aortic valve-in-valve implantation in a degenerated 19 mm Mitroflow® aortic pericardial heart valve. <i>EuroIntervention</i> , 2014, 9, 1368-1368.	1.4	7
103	Single-Center Experience and Short-term Outcome with the JenaValve: A Second-Generation Transapical Transcatheter Aortic Valve Implantation Device. <i>Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery</i> , 2014, 9, 368-374.	0.4	1
104	Interventional treatment for structural heart disease: Who is deciding, and can we afford it?. <i>Swiss Medical Weekly</i> , 2014, 144, w14046.	0.8	1
105	Drug-coated balloons for treatment of coronary artery disease: updated recommendations from a consensus group. <i>Clinical Research in Cardiology</i> , 2013, 102, 785-797.	1.5	157
106	Long-term benefits and risks of drug-eluting compared to bare-metal stents in patients with versus without chronic kidney disease. <i>International Journal of Cardiology</i> , 2013, 168, 2381-2388.	0.8	15
107	Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials. <i>Lancet, The</i> , 2013, 382, 1879-1888.	6.3	127
108	Transcatheter Aortic Valve Replacement in Europe. <i>Journal of the American College of Cardiology</i> , 2013, 62, 210-219.	1.2	199

#	ARTICLE	IF	CITATIONS
109	Long-term safety of drug-eluting stents. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 1359-1378.	0.6	5
110	Mens sana in corpore sano revisited. <i>European Heart Journal</i> , 2013, 34, 2580-2581.	1.0	5
111	By a Hair's Breadth. <i>Circulation</i> , 2013, 128, 84-85.	1.6	0
112	Predictors for efficacy of percutaneous mitral valve repair using the MitraClip system: the results of the MitraSwiss registry. <i>Heart</i> , 2013, 99, 1034-1040.	1.2	126
113	Stent Thrombosis after Coronary Stent Implantation: A Protective Effect of High-Dose Statin Therapy?. <i>Cardiology</i> , 2013, 126, 115-121.	0.6	5
114	Multivessel versus culprit vessel percutaneous coronary intervention in ST-elevation myocardial infarction: is more worse?. <i>EuroIntervention</i> , 2013, 9, 909-915.	1.4	26
115	No One-Size-Fits-All. <i>Circulation</i> , 2012, 125, 471-473.	1.6	8
116	Newest-generation drug-eluting and bare-metal stents combined with prasugrel-based antiplatelet therapy in large coronary arteries: The BAsel Stent Kosten EffektivitÄts Trial PROspective Validation Examination part II (BASKET-PROVE II) trial design. <i>American Heart Journal</i> , 2012, 163, 136-141.e1.	1.2	15
117	Coronary Artery Disease Progression Late After Successful Stent Implantation. <i>Journal of the American College of Cardiology</i> , 2012, 59, 793-799.	1.2	58
118	Heart Failure in Post-MI Patients With Persistent IRA Occlusion: Prevalence, Risk Factors, and the Long-Term Effect of PCI in the Occluded Artery Trial (OAT). <i>Journal of Cardiac Failure</i> , 2012, 18, 813-821.	0.7	3
119	Combined clopidogrel and proton pump inhibitor therapy is associated with higher cardiovascular event rates after percutaneous coronary intervention: a report from the BASKET trial. <i>Journal of Internal Medicine</i> , 2012, 271, 257-263.	2.7	45
120	Statins: have we found the Holy Grail?. <i>Swiss Medical Weekly</i> , 2012, 142, w13515.	0.8	12
121	Limited Usefulness of the Modified Academic Research Consortium Stent Thrombosis Definition for Clinical Trials. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 1151.	1.1	2
122	Early revascularization is beneficial across all ages and a wide spectrum of cardiogenic shock severity: A pooled analysis of trials. <i>Acute Cardiac Care</i> , 2011, 13, 14-20.	0.2	32
123	The Angio-Seal,® femoral closure device allows immediate ambulation after coronary angiography and percutaneous coronary intervention. <i>EuroIntervention</i> , 2011, 7, 234-241.	1.4	25
124	Drug-eluting coronary stents in clinical practice: lessons from the BAsel Stent Kosten-EffektivitÄts Trials (BASKET). <i>Swiss Medical Weekly</i> , 2011, 141, w13263.	0.8	5
125	Drug-Eluting versus Bare-Metal Stents in Large Coronary Arteries. <i>New England Journal of Medicine</i> , 2010, 363, 2310-2319.	13.9	243
126	Low Rate of Heart Failure Hospitalization after Myocardial Infarction in the Occluded Artery Trial (OAT). <i>Journal of Cardiac Failure</i> , 2010, 16, S83.	0.7	0



#	ARTICLE	IF	CITATIONS
127	Drug-eluting stents for saphenous vein graft lesions: useful or harmful?. <i>EuroIntervention</i> , 2010, 5, 647-648.	1.4	0
128	Drug-Eluting Stents Compared with Bare Metal Stents Improve Late Outcome after Saphenous Vein Graft but Not after Large Native Vessel Interventions. <i>Cardiology</i> , 2009, 112, 49-55.	0.6	57
129	Ischaemic mitral regurgitation. <i>European Heart Journal</i> , 2009, 30, 1573-1573.	1.0	0
130	Drug-eluting stents and glycoprotein IIb/IIIa inhibitors in vessels at low anatomic risk: A retrospective analysis of previously published data from the Basel Stent Kosten Effektivitäts Trial. <i>Clinical Therapeutics</i> , 2009, 31, 2886-2893.	1.1	4
131	Early and late increased bleeding rates after angioplasty and stenting due to combined antiplatelet and anticoagulant therapy. <i>EuroIntervention</i> , 2009, 5, 425-431.	1.4	25
132	A Comparison of the Blood Pressure Changes of Lumiracoxib With Those of Ibuprofen and Naproxen. <i>Journal of Clinical Hypertension</i> , 2008, 10, 592-602.	1.0	8
133	Outpatient Rehabilitation in Patients With Coronary Artery and Peripheral Arterial Occlusive Disease. <i>Archives of Physical Medicine and Rehabilitation</i> , 2008, 89, 618-621.	0.5	27
134	Long-term benefit-risk balance of drug-eluting vs. bare-metal stents in daily practice: does stent diameter matter? Three-year follow-up of BASKET. <i>European Heart Journal</i> , 2008, 30, 16-24.	1.0	99
135	Ten-Year Trends in the Incidence and Treatment of Cardiogenic Shock. <i>Annals of Internal Medicine</i> , 2008, 149, 618.	2.0	309
136	Hemodynamic Parameters Are Prognostically Important in Cardiogenic Shock But Similar Following Early Revascularization or Initial Medical Stabilization. <i>Chest</i> , 2007, 132, 1794-1803.	0.4	33
137	Oral Hypoglycemics: Increased Postoperative Mortality in Coronary Risk Patients. <i>Cardiology</i> , 2007, 107, 296-301.	0.6	5
138	Causes of death and re-hospitalization in cardiogenic shock. <i>Acute Cardiac Care</i> , 2007, 9, 25-33.	0.2	36
139	Cost-effectiveness of drug-eluting stents in patients at high or low risk of major cardiac events in the Basel Stent Kosten Effektivitäts Trial (BASKET): an 18-month analysis. <i>Lancet</i> , The, 2007, 370, 1552-1559.	6.3	91
140	Benefit of outpatient cardiac rehabilitation in under-represented patient subgroups. <i>Acta Dermato-Venereologica</i> , 2007, 39, 246-251.	0.6	18
141	Late Clinical Events After Clopidogrel Discontinuation May Limit the Benefit of Drug-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2006, 48, 2584-2591.	1.2	1,242
142	Interhospital transfer for early revascularization in patients with ST-elevation myocardial infarction complicated by cardiogenic shock—a report from the Should we revascularize Occluded Coronaries for cardiogenic shock? (SHOCK) trial and registry. <i>American Heart Journal</i> , 2006, 152, 686-692.	1.2	30
143	Long-term prognostic value of the preoperative 12-lead electrocardiogram before major noncardiac surgery in coronary artery disease. <i>American Heart Journal</i> , 2006, 151, 508-513.	1.2	68
144	Selection bias of elderly patients with chronic angina referred for catheterization. <i>International Journal of Cardiology</i> , 2006, 110, 80-85.	0.8	7

#	ARTICLE	IF	CITATIONS
145	Randomized, Double-Blind Comparison of Acute $\beta$ 1-Blockade With 50 mg Metoprolol Tartrate vs 25 mg Carvedilol in Normal Subjects. <i>Congestive Heart Failure</i> , 2006, 12, 254-257.	2.0	6
146	Emergency revascularization in patients with cardiogenic shock on admission: a report from the SHOCK trial and registry. <i>European Heart Journal</i> , 2006, 27, 664-670.	1.0	87
147	Influence of Revascularization on Long-Term Outcome in Patients $\geq$ 75 Years of Age With Diabetes Mellitus and Angina Pectoris. <i>American Journal of Cardiology</i> , 2005, 96, 193-198.	0.7	8
148	Lumiracoxib, a highly selective COX-2 inhibitor. <i>Expert Review of Clinical Immunology</i> , 2005, 1, 37-45.	1.3	6
149	Prognostic Value of Stress Testing in Patients Over 75 Years of Age With Chronic Angina. <i>Chest</i> , 2004, 125, 1124-1131.	0.4	23
150	Heart rate variability and cardiac troponin I are incremental and independent predictors of one-year all-cause mortality after major noncardiac surgery in patients at risk of coronary artery disease. <i>Journal of the American College of Cardiology</i> , 2003, 42, 1767-1776.	1.2	106
151	Long-term outcome of patients with silent versus symptomatic ischemia six months after percutaneous coronary intervention and stenting. <i>Journal of the American College of Cardiology</i> , 2003, 42, 33-40.	1.2	100